An Examining Progress in Research: Cost-effectiveness of Cardiovascular Disease Prevention Using the Markov Model
Article Sidebar
Main Article Content
Abstract
This article reviews three-volume collection of previously published articles on cost-effectiveness in cardiovascular disease prevention. Firstly, cost–effectiveness analysis of genetic screening for the Taq1B polymorphism in the secondary prevention of coronary heart disease is conducted. Secondly, a “polypill” aimed at preventing cardiovascular disease could prove highly cost-effective for use in Latin America, and lastly, the cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany is assessed, based on the Treating to New Targets study. All three articles in this paper demonstrate how the Markov model can control strategy in terms of cost savings and increase the mean of quality-adjusted life-years (QALYs). Moreover, the Markov model can be used to demonstrate how healthcare systems can control the cost-effectiveness of drug use in terms of cardiovascular disease related to health benefits, costs, and quality-adjusted life-years (QALYs). In conclusion, employing the Markov model through other interventions, especially in the case of health benefits, cost savings, and quality-adjusted life-years (QALYs) is the main recommendation of this article.
Keywords: Markov Model, Cardiovascular Disease Prevention, Cost Effectiveness
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
- Under a CC Attribution-NonCommercial-NoDerivatives 4.0 (CC BY-NC-ND 4.0) license, you can copy, distribute, display, perform, and use any published material (figures, schemes, tables or any extract of a text) for any purpose other than commercially (unless you get permission first).
- Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by the journal (including the editor, any member of the editorial team or editorial board, and any guest editors).
- The editor has the right to edit the content of the manuscript to make it suitable for publication.
References
Australian Institute of Health and Welfare. (2004). Heart, stroke and vascular diseases, Australian facts. https://www.aihw.gov.au/reports/heart-stroke-vascular-diseases/australian-facts-2004/summary
Bautista, L. E., Vera-Cala, L. M., Ferrante, D., Herrera, V. M., Miranda, J. J., Pichardo, R., Sánchez Abanto, J. R., Ferreccio, C., Silva, E., Oróstegui Arenas, M., Chirinos, J. A., Medina-Lezama, J., Pérez, C. M., Schapochnik, N., & Casas, J. P. (2013). A “polypill” aimed at preventing cardiovascular disease could prove highly cost-effective for use in Latin America. Health Affairs (Project Hope), 32(1), 155–164. https://doi.org/10.1377/hlthaff.2011.0948
Briggs, A., & Sculpher, M. (1998). An Introduction to Markov modelling for economic evaluation. Pharmacoeconomics, 13(4), 397-409.
D’Agostino, R. B., Vasan, R. S., Pencina, M. J., Wolf, P. A., Cobain, M., Massaro, J. M., & Kannel, W. B. (2008). General cardiovascular risk profile for use in primary care: The Framingham Heart Study. Circulation, 117(6), 743–753. https://doi.org/10.1161/CIRCULATIONAHA.107.699579
Dirogtornsakul, P., & Chaiyakunapreuk, N. (2016). Decision analysis model II: Markov model and Uncertainty management (in Thai). https://ccpe.pharmacycouncil.org/showfile.php?file=225
Kemp, K., Doran, M., Vos, T., & Hall, W. (2007). Cost-effectiveness analysis of genetic screening for the Taq1B polymorphism in the secondary prevention of coronary heart disease. Expert Rev. Phamacoeconomics Outcomes,7(2), 119-128.
Taylor, D. C. A., Pandya, A., Thompson, D., Chu, P., Graff, J., Shepherd, J., Wenger, N., Greten, H., Carmena, R., Drummond, M., & Weinstein, M. C. (2009). Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study. The European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care, 10(3), 255–265. https://doi.org/10.1007/s10198-008-0126-1
Usher, M. B. (1981). Modelling ecological succession, with particular reference to Markovian models. Vegetatio, 46(1), 11–18. https://doi.org/10.1007/BF00118380
Wallisch, P., Lusignan, M. E., Benayoun, M. D., Baker, T. I., Dickey, A. S., & Hatsopoulos, N. G. (2014). Chapter 32—Markov Models. In P. Wallisch, M. E. Lusignan, M. D. Benayoun, T. I. Baker, A. S. Dickey, & N. G. Hatsopoulos (Eds.), MATLAB for Neuroscientists (Second Edition) (pp. 449–462). Academic Press. https://doi.org/10.1016/B978-0-12-383836-0.00032-1
Indian Polycap Study (TIPS), Yusuf, S., Pais, P., Afzal, R., Xavier, D., Teo, K., Eikelboom, J., Sigamani, A., Mohan, V., Gupta, R., & Thomas, N. (2009). Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): A phase II, double-blind, randomised trial. Lancet (London, England), 373(9672), 1341–1351. https://doi.org/10.1016/S0140-6736(09)60611-5